This content is only available within our institutional offering.
23 Sep 2019
NOVO NORDISK: Oral semaglutide approved as Rybelsus in the US and to be priced as an injectable | NEUTRAL | DKK365 vs. DKK358 (+2%)
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
NOVO NORDISK: Oral semaglutide approved as Rybelsus in the US and to be priced as an injectable | NEUTRAL | DKK365 vs. DKK358 (+2%)
Novo Nordisk A/S Class B (NNO2:WBO) | 0 0 2.2% | Mkt Cap: 611,927m
- Published:
23 Sep 2019 -
Author:
Eric Le Berrigaud -
Pages:
3
NOVO NORDISK - NEUTRAL | DKK365 vs. DKK358 (+2%)
Oral semaglutide approved as Rybelsus in the US and to be priced as an injectable
Rybelsus carries the same label as injectable GLP1s
Instructions for administration to be more cumbersome
Novo-Nordisk has to position it right into the portfolio